Evidence map›Paper›PMID 36754716›Full record

ReviewZeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen2023

[Development and validation of potential structure indicators for clinical infectious disease (ID) care in German hospitals during the COVID-19 pandemic].

Lene Tscharntke, Melanie Stecher, Annika Y Classen, Norma Jung, Lukas Eberwein, Anette Friedrichs, Hartwig Klinker, Maximilian J Schons, Christoph D Spinner, Maria J G T Vehreschild and 2 more

Open access · greenAbstract readReviewEnglish Abstract
In one paragraph

Review in Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Lene TscharntkeUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland.
Melanie StecherUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland; Deutsches Zentrum für Infektionsforschung (DZIF), Partnerstandort Bonn-Köln, Köln, Deutschland.
Annika Y ClassenUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland; Deutsches Zentrum für Infektionsforschung (DZIF), Partnerstandort Bonn-Köln, Köln, Deutschland.
Norma JungUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland.
Lukas EberweinKlinikum Leverkusen, Medizinische Klinik IV, Leverkusen, Deutschland.
Anette FriedrichsUniversitätsklinikum Schleswig-Holstein, Klinik für Innere Medizin I, Campus Kiel, Kiel, Deutschland.
Hartwig KlinkerUniversität Würzburg, Medizinische Klinik und Poliklinik II, Infektiologie, Würzburg, Deutschland.
Maximilian J SchonsUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland.
Christoph D SpinnerTechnische Universität München, Fakultät für Medizin, Klinikum rechts der Isar, Klinik und Poliklinik für Innere Medizin II, München, Deutschland.
Maria J G T VehreschildKlinik für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Deutschland; Deutsches Zentrum für Infektionsforschung (DZIF), Partnerstandort Bonn-Köln, Köln, Deutschland.
Katja de WithUniversitätsklinikum Carl Gustav Carus Dresden, Klinische Infektiologie, Dresden, Deutschland.
Jörg J VehreschildUniversität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Deutschland; Deutsches Zentrum für Infektionsforschung (DZIF), Partnerstandort Bonn-Köln, Köln, Deutschland; Klinik für Innere Medizin, Hämatologie und Onkologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Deutschland. Electronic address: joerg.vehreschild@uk-koeln.de.
Centrum für Integrierte Onkologie · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DELMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study describes the development and validation of structure indicators for clinical infectious disease (ID) care in German hospitals, which is important to adequately face the future challenges in ID medicine.

methodsA team of experts developed the structure indicators in a three-stage, multicriteria decision-making process: (1) identification of potential structure indicators based on a literature review, (2) written assessment process, and (3) face-to-face discussion to reach consensus and final selection of appropriate structure indicators. A field study was conducted to assess the developed structure indicators. A score based on the structure indicators was determined for each hospital and validated via receiver operator characteristic (ROC) curves using externally validated ID expertise (German Society of ID (DGI) Centre).

resultsBased on a list of 45 potential structure indicators, 18 suitable indicators were developed for clinical ID care structures in German hospitals. Out of these, ten key indicators were defined for the general and coronavirus disease 2019- (COVID-19-) specific clinical ID care structures. In the field survey of clinical ID care provision for COVID-19 patients in 40 German hospitals, the participating facilities achieved 0 to 9 points (median 4) in the determined score. The area under the ROC curve was 0.893 (95% CI: 0.797, 0.988; p < 0.001). DISCUSSION/

conclusionThe structure indicators developed within the framework of a transparent and established development process can be used in the future to both capture the current state and future developments of ID care quality in Germany and enable comparisons.

Indexed as

Communicable DiseasesCOVID-19GermanyHospitalsHumansPandemicsCOVID-19Health care qualityHealthcare researchInfectious diseasesKlinische InfektiologieQualitätsindikatorenQuality indicatorsVersorgungsforschung

Identifiers

PMID36754716
PMCPMC9901538
OpenAlexW4319302278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.